We invite you to visit PAREXEL at these upcoming industry events. Events are a great way to get to know our experts, discuss your outsourcing challenges, and learn how PAREXEL’s global reach, technology and expertise can help your organization.
| Suggest an eNewsletter Topic |
CenterWatch 2007
The FDA, in an effort to increase new drug approvals, has identified imaging as an important technology for assessing new therapeutics and accelerating drug development in the future.
Medical imaging allows researchers to see the effect of a new drug more rapidly than possible when relying on traditional clinical endpoints. It plays an important role in an increasing number of clinical trials, and offers sponsor companies the possibility of decreasing both time and cost in getting new pharmaceutical products to market.
Sponsor companies increasingly depend on imaging to help them make "go/no-go" decisions about the products they are developing, to provide surrogate endpoints in clinical trials and to support claims about a new drug’s efficacy and safety.
Medical imaging is an increasingly important factor in the successful conduct of many clinical studies, experts claim. In addition, there has been a rise in the development of imaging core labs, which centralize quality control and assessment of images. During the past three years, these vendors have become an increasingly integral part of the clinical trial process.
Medical imaging plays an increasingly important role in the development of drugs for a variety of disease processes, including cardiovascular disease, central nervous system disease, cancer, diabetes, osteoporosis and arthritis. Use of medical imaging within a clinical trial offers the potential for more efficient and accurate evaluation of medical products and provides information not available by using traditional measurements such as quality of life.
